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INTRODUCTION 
 
GENERAL PREVIEW OF ORAL CANCER 
 Oral cancer is one of the most common malignant neoplasia  
world wide. Each year about 14 million new oral  cancer patients are 
diagnosed. The incidence rates of oral cancer are higher in men as 
compared to women. Squamous cell  carcinoma (SSC) is the most 
common histological  type of oral cancer as 90% of oral  cancers are 
originates from squamous cells 
(1 )
.   The main si tes for oral cancer 
include the lips,  gums, tongue, buccal mucosa, the floor (bottom) of 
the mouth, the hard palate (bony top of the mouth ), and gingival 
(Figure 1.1). Generally oral cancer is detected by clinical  
examination followed by biopsy of tissues for histopathological  
conformation. The development and progression of oral squamous 
cell carcinoma is a multifaceted complex disease involving 
environmental  and genetic factors.  Major risk associated factors for 
oral cancer are tobacco, betel quid and alcohol intake.  
 
  Early presentations and precancerous stage of oral  cancer are 
often observed as red or white mucosal lesions defined as oral  
erythroplakia (red) or oral  leukoplakia (white), respectively.  
Subsequently, precancerous lesions advance from hyperplasia to 
dysplasia and then to carcinoma in situ before develop into invasive 
oral malignant neoplasia
(2 )
.  Oral cancer is generally categorized 
into four types according to their tumour, node, and metastasis 
(TNM) stages. Tumour stages, T0  represent no evidence of tumour, 
T1  signify tumours less than or equal to 2 cm, T2  represent tumour 
greater than 2 cm, T3 represent greater than 4 cm and tumours are 
considered T4  i f  tumours have invaded surrounding areas. 
Moreover,  number of lymph nodes (N) and distant sites (M) 
occupied by the tumours are also included in the TNM classification 
of oral  cancer 
(3 )
.  According to Border 's system of grading, tumours 
were graded on the basis of the degree of differentiation and 
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keratinization of tumour cells into four groups,  namely grade -I 
(Well differentiated tumours), grade -II (Moderately differentiated 
tumours),  grade-III (poorly differentiated tumours) and grade -IV 
(Anaplastic tumours) 
(4 ,5 )
.  
 
 
Figure 1.1:A-showing OSCC of the Tongue and B-showing OSCC 
of the Soft Palate;  and C&D- showing OSCC of the Alveolar 
Mucosa 
 
Over the past  two decades,  in spite of the medical 
advancements in local control  and the use of different combined 
therapies,  the survival rates for oral  cancer have not enhanced 
significantly.  Delay in diagnosis is one of the major factor  for low 
survival rate in oral cancer patients.  Therefore, novel diagnostic  
methods of oral cancer need to be developed for early detection and 
therapy 
(6 )
.  A better understanding of mechanisms leading to OSCC 
is needed to develop more effective diagnostic and therapeutic 
methods for oral  cancer.   
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Prevalence of oral cancer  
In India 
 In India, oral cancer is the most common malignancy amongst 
men (11.28% of all  cancers),  fifth most cancer amongst women 
(4.3% of all cancers) and the third most common cancer among men 
and women. The mean age of oral cancer was 50 years. About 80% 
of oral cancers are mainly attributable to tobacco consumption 
(7 ,  8 )
.  
 
 In India,  the prevalence of cancer was maintaining through by 
two cancer registry: 1) hospital -based cancer registries, and 2) 
population-based cancer registries (PBCRs). PBCRs provide 
information about the etiology, burden of cancer and the 
effectiveness of the treatments that have been undertaken to control 
cancer. PBCRs are the only data source which delivers authentic 
information on the mortality and incidence of any cancer in India.  
According to the cancer registry,  the overall  incidence of oral 
cancer is  highest  in the central  region of India.  In males,  the 
prevalence of oral cancer is 64.8% and in females 37.2% at age of 
70 years. The next highest prevalence of oral cancer was observed 
in northeast regions and west (about 60%) at age of 60 years 
(9 )
.  
Data indicators like age-adjusted rates (AARs) of oral cancer 
occurrence of male and female in each of the 29 registries of PBCRs 
were obtained from National Cancer Registry Programme (NCRP) 
source and were represented region -wise.  According to cancer 
registry in India, age-adjusted rate (AAR) of mouth cancer is  the 
highest  in the central region among males (64.8%) in the age group 
60-69 years fol lowed by west and northeast regions of India with 
AAR of 58.4%. Among females,  oral cancer is  the highest  in the 
northeast and central regions (60.2% and 37.2%, respectively),  in 
the age group of 70-75-years AAR also indicates increasing 
incidence of oral  cancer with age. Among the different type of oral  
cancers,  AAR of mouth and tongue cancers in males display cases at  
a very early age group (0–20 years) part icularly in the western 
region PBCRs, which followed by the north region 
(1 0 )
.  
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World 
 Globally,  369,200 new cases of oral cancers were reported 
with two-thirds of the oral cancers identified in developing 
countries. Worldwide oral cancers are responsible for about 145,328 
deaths per year.  The highest incidence of oral  cancers is mostly 
reported from South and Southeast Asia. The prevalence of OSCC 
varies significantly, depending on geographical  areas while 
diagnosed (11).  Higher incidence of oral cancer is seen in South and 
Southeast Asia includes Pakistan, India,  Taiwan and Sri Lanka and 
parts of the West includes France. As well as,  in Eastern Europe 
includes Slovenia,  Hungary, and Slovakia, and Latin America and 
the Caribbean includes Uruguay, Brazil and Puerto Rico and also in 
Pacific countries such as Papua New Guinea and Melanesia.  
According to the Human development index of the United Nations 
Development Programme (UNDP), the incidence also differs.  Based 
on this index, the incidence is greater in countries with improved 
growth indicators. The GLOBOCAN grouping exposes that  the crude 
rate and age-standardized incidence rate (universally) are greater in 
most developed countries, but death rate is superior in less 
developed countries,  which exposes social inequality (2).  
 
Risk factors in oral cancer  
 Cigarette smoking and alcohol consumption are the major risk 
factors for oral cancer and are reported to play a synergistic role in 
increasing the risk for oral cancer. Tobacco smoke contains various 
carcinogenic elements which can be basically grouped int o 3 
groups: nitrosamines, aromatic amines,  and benzo -pyrenes (BAP) 
(1 2 )
.  These elements are termed as pre -carcinogens which when 
undergoes oxidative, enzymatic and other non -enzymatic 
modifications transforms into electron deficient secondary products 
that  can form an adduct in the DNA by covalent bonding 
(1 3 )
.  
According to the International Agency for Research on 
Cancer (IARC), 2007 report , snuff consumption was related to the 
increased risk for oral  and pancreatic cancer.  Snuff consumption 
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may lead to the damage of the oral  epithelium due to the increased 
production of oxygen and nitrogen free radicals.  So me of the most 
important carcinogenic aromatic hydrocarbons present in tobacco 
smoke are the benzo-pyrene and the tobacco-specific nitrosamines 
such as 4-(nitrosomethylamino) -1-(3-pyridyl)-1-butanone (NNK) 
and N’-nitrosonornicotine (NNN) (1 4 ) .  
 
 Alcohol is an important risk factor for oral  cancer which not 
only acts locally but also systematically by increasing the oral  
mucosal permeabili ty,  dissolving epithelial lipid components 
leading to epithelial atrophy as well  as impaired DNA synthesis and 
repair. Alcohol has also been reported to have both genotoxic and 
mutagenic effects affecting the salivary flow as well as the abili ty 
of the liver to detoxify potential  cancer -causing compounds in the 
body. Regular consumption of alcohol has been found to  be 
associated with impaired innate and acquired immunity which may 
cause increased vulnerability to infections and neoplasms 
(1 5 )
.  
 
 The chewing of betel leaf is  a common traditional practice in 
many Southeast Asian countries, especially in India where it is 
consumed along with other ingredients l ike areca nut, tobacco, and 
lime. It is commonly termed as betel quid. In countries like 
Thailand, various other ingredients such as cardamom, aniseed or 
cloves are also added to the betel quid. In India, apart from betel 
quid tobacco is also consumed in various other forms such as 
khaini ,  mishri ,  zarda ,  mawa  and guthka .  In Central Asia and the 
Middle East,  tobacco is consumed in the form of nass and 
naswar/niswar respectively.  In Saudi Arabia and Sudan, it  is  
consumed as shammah  and toombak  respectively 
(1 6 )
.  Various 
reports have previously described the associ ation of tobacco 
consumption with the increased risk for oral cancer and pre -
cancerous stages such as oral submucous fibrosis, erythroplakia,  and 
leukoplakia 
(1 7 )
.  Many previous studies have been focused on 
understanding the carcinogenic and mutagenic capability of the 
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betel  nut and tobacco products.  In vitro studies on oral mucosal  
fibroblasts using DNA damage, cytotoxicity,  and cell proliferation 
assays have shown that some essential betel quid ingredients are 
genotoxic, cytotoxic, and also stimulate cell proliferation. Elevated 
reactive oxygen species and methylating agents produced due to 
betel quid consumption have been observed to induce various DNA 
damage in the oral  mucosa cells 
(1 8 )
.  
 
 The role of diet and nutrition in modifying the risk for cancer 
has been well established by various previously conducted 
epidemiological and laboratory studies.  According to the IARC 
report, it  has been affirmed that individuals with low fruits and 
vegetable consumptions habits are at  an increased risk for 
development of cancer 
(1 9 )
.  Studies have shown that frequent 
consumption of green vegetable as well as carrots and tomatoes 
helps in reducing the risk for oral and pharyngeal cancer.  Food and 
food groups other than fruits and raw vegetables that  have a 
protective effect  are fish, vegetable oil, olive oil, etc.  However,  
foods like processed meats, eggs, butter, cakes, etc. have been 
reported to be associated with increased cancer risk 
(2 0 )
.  
 
 Studies have reported interplay of the dietary habits with the 
cultural  risk factors in modifying the risk for oral  cancer and pre-
cancerous stages. Cigarette smokers have been found to have 
decreased β-carotene levels in comparison to the nonsmokers. The 
serum levels of Vitamin A, C, B12, folate, and β -carotene has been 
found to be lower among betel quid chewers in comparison to the 
levels in the non-betel quid chewers 
(1 2 )
.  
 
 Viruses have been found to be strongly associated with the 
onset of malignant oral squamous epithelium tumours.  Viral 
infections may interfere with the host’s cellular machinery and may 
induce malignancy in the normal cells of the body. These viral 
genes and gene products may affect cell growth and proliferation. 
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Viral  genes are mostly present as proto -oncogenes which when gets 
incorporated into the host’s DNA turns into oncogenes resulting in 
the transformation of the normal cell into malignant cells. The most 
important viruses linked with oral  malignancy are the Epstein –Barr 
virus, human papillomavirus (HPV), and herpes virus 
(1 2 )
.  
 
 In oral cancers, the most commonly found type is the HPV 16 
which encodes E6 and E7 oncoproteins.  These proteins bind to the 
p53 and Rb tumour suppressor genes and destroy them, thus leading 
to the impairment of the cell  cycle and DNA repair pathways 
( 2 1 )
.  
 
Biomarkers of oral cancers  
 Cancer biomarker refers to genetic, proteomic and epigenetic 
characteristics that  indicate the presence of cancer. A cancer 
biomarker may be a substance secreted by a  tumour or by a 
particular response of the body to the manifes tation of 
cancer.  Recent research studies revealed that  increased levels of 
interleukin-8 can be used to recognize OSCC patients from non -
OSCC patients, with high specificity 
(2 2 ) .
 Malignant transformation 
of dysplasia prediction is also used as a useful marker for oral 
cancer detection. Recent studies revealed that  loss -of-
heterozygosity (LOH) of chromosomes 3p and 9p is a predictive 
marker in OSCC risk  
(2 3 )
.  
 
 Several  tumour suppressing genes have been found and 
recognized in OSCC progression, for example - p53 ,  E-cadherin ,  and 
p120- catenin .  Whereas, the increased activities of tumour 
promoters like EGFR, cyclin D1, Src tyrosine kinases, 
transmembrane receptor podoplanin are frequently found. 
Especially, podoplanin has appeared as a potential biomarker and 
functionally relevant therapeutic biomarker to treat and prevent oral  
cancer 
(6 )
.  
 
 
Introduction 
 
 8 
 
Podoplanin and its role in cancer  
 Podoplanin is a type-1 transmembrane glycoprotein (38kDa), 
and the name podoplanin was termed due to its  expression in kidney 
podocytes and in the regulation of podocyte  foot processes . 
Podoplanin has an extensive variety of functions including 
regulation of cell  motility,  organ development,  and tumuorigenesis 
and metastasis.  Podoplanin has an important role in inhibition of 
cellular adhesion, flattening of podocyte foot processes and the 
maintenance of glomerular permeability.  It has been found to 
associated with oral , lung, skin, lung, and esophageal cancer 
(2 4 )
.  
Podoplanin gene is 34.2 kilobase  (Kb) with 8 exons, which encode 
podoplanin protein.  The sub-cellular location of the podoplanin is  in 
the plasma membrane. Two different species of podoplanin mRNA 
were recognized by northern blotting that  possibly initiates from 
alternative splicing. Podoplanin is highly expressed in lymphatic 
endothelium, but does not express in the blood vessel  endothelium. 
Moreover,  it  is  also expressed in a variety of neoplastic human 
tissues.  Podoplanin was detected in many human normal tissues,  
including lymphatic heart,  endothelial cells, muscle,  lung, placenta, 
myoepithelial  cells of glands, follicular dendritic Schwann cells 
(2 5 )
.  
It  also identified in the development of tooth germ and 
odontogenesis regulation 
(2 6 )
.   
 
 Podoplanin protein consists of 162 a.mino  acids, with a single 
transmembrane region, a four extracellular platelet aggregation -
stimulating domain (PLAG) with threonine and serine residues,  and 
a cytoplasmic carboxyl tail,  also having sites for cAMP and protein 
kinase C phosphorylation 
(2 7 ) .
 Podoplanin does not have enzymatic 
activities or functional domains. Therefore it uses other proteins,  
such as CLEC-2 (C-type lectin-l ike receptor-2), CD44, HSPA9 (heat 
shock protein A9),  CCL21 (C-C motif chemokine ligand 21),  
galectin 8, ezrin,  moesin,  CDK5 (cyclin dependent kinase 5),  and 
PKA (protein kinase A). Podoplanin interact  with these binding 
partners and ligands to control tumour cell mobility,  invasion and 
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metastasis. Podoplanin mainly induces platelet  aggregation by 
binding to CLEC‐2, which expressed on the platelet  surface.  
 
 A motif in the transmembrane region drives podoplanin to 
form a homodimer and circulate to lipid rafts. Different ligands and 
binding agents like CLEC2, HSPA9, CD44, Galectin  8, and CCL21 
bind to extracellular domains of podoplanin. CLEC2 contact sites 
have been localized to podoplanin residues D48, G45, and D49, with 
the help of glycosylation at T52, along with E81, T85, and D82 in 
PLAG4 domain. Tetraspanin CD9, the integral membrane protein 
interacts with the podoplanin transmembrane domain. Ezrin and 
moesin proteins interact with the podoplanin cytoplasmic tail to 
control ROCK/LIMK pathways activities as well  as actin 
polymerization by Rho GTPases. The CDK5 and PKA can 
phosphorylate intracellular serines to inhibit  tumour cell  motility.  
Podoplanin expressed on the surface of tumour cells induces platelet 
aggregation by interacting with CLEC-2 and may regulate tumour 
invasion and metastasis and therefore,  podoplanin might be a  
potential target  for therapy of metastasis. Podoplanin expression is 
also induced by tumour promoters like RAS, TPA, and Src. Src is a 
non-receptor protein kinase that promotes cancer cell growth and 
migration required for metastasis. Therefore,  podoplanin plays a 
vital role in many cancer and in lymphatic vascular development 
metastasis through interaction with CLEC ‐2 (2 8 ) .  Podoplanin  is also 
expressed in cancer ‐associated fibroblasts (CAF) where i t  allows 
adenocarcinoma cell invasion in the lung by activating the 
Rho‐ROCK pathway (2 9 ) .  
 
Podoplanin and squamous cell carcinoma  
 Podoplanin includes an extracellular region, transmembrane  
domain, and intracellular (IC) tail .  CLEC -2 interacts with PLAG 
domains in the extracellular region to induce inflammation and 
tumour progression, and this interaction can be obstructed by 
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antibodies, including NZ-1, MS-1 and podoplanin antibodies 
(CasMabs). Antibodies can also target podoplanin in order to stop 
transformed cell  growth and motili ty directly,  or can be 
incorporated into CAR-T cells.  Lectins represented by MASL can 
also target podoplanin to block the tumour progression and 
inflammation. Protein kinase A (PKA) and cyclin dependent kinase 
5 (CDK5) can phosphorylate serines on the intracellular tail  to 
block cell  migration, probably by inhibiting interaction of ERM 
proteins that would otherwise lead to the activation of Rho GTPases 
and Rho-associated coiled-coil kinase (ROCK). Podoplanin 
expression induces ROCK activity to promote squamous cell 
carcinoma survival and colony expansion 
(3 0 )
.   
 
Markers Useful for Identification of Podoplanin  
 The podoplanin expression is detected mainly by 
immunohistochemistry and the most commonly used antibodies is  
D2-40, which identifies the formalin -resistant epitope of  
podoplanin. In both normal and neoplastic t issues, double 
immunostaining based on antiD2-40 or anti -podoplanin and CD34 
confirmed that  the final product of reaction for podoplanin. 
Podoplanin-positive samples are also stained with an antibody 
antiVEGFR-3, and the final product is mostly found at the luminal 
surface. Lymphatic endothelial cell s  can be considered as 
podoplanin-expressing cells that express CD34 at  very low levels.  
 
Podoplanin as Marker of Lymphatic Endothelial  Cells (LECs)  
 Since podoplanin is  expressed mainly by lymphatic 
endothelium and not by normal blood vessel endothelium, therefore,  
podoplanin is  extensively used as a specific marker to evaluate 
lymphatic vessel invasion and lymphatic microvessel  density.  
Lymphatic vessel invasion (LVI) and lymphatic microvessel  density 
(LMVD) have been found to associate with lymph node me tastasis,  
advanced stage, low survival in various cancers,  including oral 
squamous cell carcinoma 
(3 1 )
.  Podoplanin binds with the CLEC2 
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receptor on platelets and this binding makes lymphatic sacs to 
remove and separates it  from cardinal veins.  This separ ation is very 
important for the lymphatic system to emerge from the embryonic 
cardiovascular system, which sustains beyond development. 
Numerous lymphatic endothelial markers, includes prospero -related 
homeobox-1 (Prox-1),  podoplanin, vascular endothelial  growth 
factor receptor-3 (VEGFR-3), and lymphatic vessel endothelial 
hyaluronic acid receptor -1 (LYVE-1) are broadly utilized in the 
diagnosis of lymphangiogenesis and LVI in several  types of cancer 
including oral cancer. These biomarkers bind with each ot her in 
several physiological  processes.  
 
 It  was observed that  the level of VEGFR -3 substantially high 
in lymphatic endothelial cells,  whereas its expression is decreased 
in vascular endothelial cells. Specific markers of lymphatic 
endothelial cells, VEGFR-3, LYVE-1, Prox-1 and podoplanin, have 
provided new direction into the cancer diagnostic and therapeutic.  
Many prior studies have reported the co -expression of, VEGFR-3, 
Prox-1 and LYVE-1 podoplanin in lymphatic endothelial cells of 
normal adult  and tumour tissues 
(3 2 )
.  
 
Podoplanin expression in oral cancer  
 Combined analysis of around 1,000 samples revealed that  
podoplanin expression was very low in normal oral epithelial cells,  
but was found higher in oral  cancers 
(6 )
.  Furthermore, podoplanin  
expression in oral cancers is expected to be much higher than 
actually reported. This is  due to podoplanin expression is observed 
mostly in the invasive sites of oral cancers.  Many previous studies 
also reported very high podoplanin expression in OSCC 
( 3 3 ,  3 4 )
. 
Podoplanin expression is induced very early in the malignant 
transformation process, and therefore may be used to detect  
premalignant lesions that are bound to develop into oral  cancer.  
Pooled analysis of many retrospective studies on premalignant oral  
lesions summarized that over 46% of lesions with prominent 
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podoplanin expression advanced to OSCC. However, very less 
percentage (14%) of lesions without prominent podoplanin 
expression progressed to OSCC. These results indicate that 
podoplanin expression elevates the probabili ty of OSCC 
development by over 3-fold 
(6 )
.  
 
 Since more suspicious lesions of OSCC are mainly selected 
for biopsy, these results of podoplanin expression could be 
underestimated. Previous study also supported these 
underestimation of Podoplanin expression as about 80% of oral 
leukoplakia as that  express high levels of podoplanin develop into 
oral cancer 
(3 5 )
.  Moreover podoplanin expression also associates 
with OSCC mortali ty, as five year overall  survival declines from 86 
percent for patients with tumours with undetectable expression of 
podoplanin levels to 23 percent for cases with tumours exhibiting 
upregulated podoplanin expression 
(3 6 )
.  These finding demonstrated 
that podoplanin expression promote an around threefold decrease in 
five year survival for oral  cancer patients. Podoplanin is  expressed 
in many forms of cancer. Expression of podoplanin expression in 
OSCC is also associated with lymph node metastasis and poor 
prognosis 
(3 7 )
.  It  also associates with sentinel lymph node metastasis 
in early OSCC 
(3 8 )
.  Nevertheless, one of the studies demonstrated 
that expression of podoplanin didn't influence the five -year overall 
survival or the five-year disease-free survival 
(3 9 )
.  A study 
demonstrated that dual expression of podoplanin in tumour cells and 
lymphatics with specific patterns connected with histopathology and 
lymph node status in oral cancer,  exhibiting the molecular basis for 
testing podoplanin as  a potential target for anti D2-40 antibody 
based therapy 
(4 0 )
.
 
 
 Furthermore, another study also reported a high level of 
podoplanin expression is indicative of high incidence of lymph node 
metastasis and immature status in the differentiation process of 
OSCC. They also demonstrated that podoplanin could be a potential  
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biomarker in evaluating the cytoplasm -membrane staining of tumour 
cells 
(4 1 )
.  Another previous analysis also described that podoplanin 
can be utilized as a biomarker for early oral carcinogenesis and for 
malignant transformation risk identification of pre -cancerous 
lesions and as a tumour development biomarker for advanced grades 
of OSCC 
(4 2 )
.  Previous study analyzed the podoplanin expression of 
oral squamous cell  carcinoma (OSCC), oral  leukoplakia, oral  
submucous fibrosis and normal buccal mucosa, using monoclonal 
antibody D2-40 and found that there was a statisti cally significant 
upregulation of podoplanin expression in OSCC (100%), oral 
submucous fibrosis (90%) and oral leukoplakia (65%) as compared 
with normal mucosa (35%) 
(4 3 )
.  
 
Podoplanin as therapeutic target  
 Podoplanin has appeared as an obvious chemotherapeutic 
target for oral cancer.  Therefore,  compounds that  target  podoplanin 
are being enhanced as anti -cancer reagents.  This comprises 
antibodies and cell -based immunotherapies.  Antibodies against 
podoplanin have exposed potential  as anticancer agents in previous 
experimental  studies. This experiment started with the NZ -1 
monoclonal antibody that targets the PLAG domains of human 
podoplanin. At first, NZ-1 was established to obstruct  platelet  
aggregation to glioma cells mediated by podoplanin -CLEC2 
interactions.  A mouse-human chimeric antibody against human 
podoplanin, chLpMab-7, was also exposed to obstruct  metastasis in 
a pulmonary xenograft  mouse model. Other anti -Podoplanin 
monoclonal antibodies such as muri ne and humanized MS-1 also 
numb Podoplanin-CLEC2 interactions and can efficiently obstruct 
lung tumour development by intravenous administration.  
 
 Genetically modified chimeric antigen receptor (CAR) -
transduced T-cells that target podoplanin have also been revealed to 
obstruct glioblastoma progression in mouse models. For instance, 
human T cells expressing modified NZ-1 administered into the tail 
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vein for seven days after glioblastoma implantation produced a 3 -
fold decrease in tumour development and 140 pe rcent extended 
lifetime than controls. Interestingly,  the glycosylation pattern of 
podoplanin seems to change when expressed by cancerous cells,  
leading to the growth of cancer specific monoclonal antibodies 
(CasMabs). These well specific reagents produce improved potential  
to target podoplanin on cancer cells. For instance, the CasMab 
reacts with glioblastoma, mesothelioma, and lung cancer cells. This 
technology was also used to enhance chLpMab -23, which can 
obstruct glioblastoma and OSCC development. For instance, human 
OSCC cells that were subcutaneously administered into exposed 
mice, followed by 100 µg of i.p.  administered ChLpMab -23, 6 times 
above 35 day period revealed a 3.5 -fold decrease in tumour weight 
than controls.  This precursor of this CasMab a ntibody, LpMab-23, 
also displays minimum binding to nearby lymphatic endothelial 
cells which express podoplanin. These cancer -specific podoplanin 
antibodies cause minimum offsi te targeting to offer a double -edged 
tool that can be used expression in normal tissues,  and also as 
potential  chemotherapeutic agents with reduced side effects. 
Podoplanin can also be targeted with other biological chemicals,  
represented by Maackiaamurensis seed lectin (MASL). This 
compound is essentially an unintentional component o f traditional 
medicines used to treat cancers that have been made from the 
Maackiaamurensis for decades. The relationship between MASL and 
NZ-1 show that both obstruct OSCC cell  migration and viability at  
similar concentrations of nM and µM, respectively.  Though, MASL, 
which binds terminal sialic acid residues on podoplanin,  can be 
injected via mouth to treat cancer and dynamically targets OSCC 
cells within minutes of exposure. This potential for topical and 
systemic treatments could be especially valuable for oral cancer and 
precancerous lesions that are intended to develop into OSCC 
( 6 ,  3 2 )
.  
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Rational of the study 
 Oral  cancer is  a devastating disorder that affects mill ions of 
people and their families. Over ninety percent of oral cancers are 
OSCC. The lack of efficient chemotherapeutics is  a supreme 
problem facing this patient population. Podoplanin has appeared as 
a functionally pertinent chemotherapeutic target and biomarker. 
Testing agents are being developed to particularly target this 
extracellular receptor on cancer cells while reducing the 
chemotherapeutic target  risk factors. The oral  health community is 
now ready to take benefits  of these technologies to better detect , 
treat , and prevent oral cancer. Over the past  two decades,  in spite of 
the medical advancements in local  control and the use of different 
combined therapies,  the survival rates for oral  cancer have not 
enhanced significantly. Recent studies have also shown that  
podoplanin may be expressed in certain tumour cells,  including 
squamous cell carcinoma cells, 8 -10 raising a possibility that 
podoplanin may have biological role in tumour cells.  Monoclon al 
antibody D2-40 has been used to identify podoplanin expression in 
tissue samples with primary oral cancer and potential correlations 
between the expression and clinical and pathological features. Delay 
in diagnosis is one of the major causes for low sur vival rate in oral  
cancer patients. Therefore,  novel diagnosis methods of oral cancer 
need to be developed for early diagnosis and therapy 
(6 )
.  A better 
understanding of mechanisms leading to OSCC is required to 
improve efficiency of diagnostic and therapeutic methods for oral 
cancer.   
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AIM AND OBJECTIVES  
 
1.  To evaluate the expression of Podoplanin Marker in oral 
squamous cell carcinoma.  
2.  To evaluate the expression of Podoplanin Marker in normal 
tissue (alveolar mucosa).  
3.  To evaluate the association of podoplanin  expression with 
different habits -related and clinicopathological  factors.  
4.  To aid in assessing the progression of oral squamous cell 
carcinoma and its adjuvant role in therapy.  
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REVIEW OF LITERATURE 
 
Podoplanin overview  
 Podoplanin is  a unique transmembrane glycoprotein receptor.  
Podoplanin contains heavily glycosylated amino terminal extra 
cellular domain of approximately 130 amino acids, followed by a 
single transmembrane domain of approximately 25 amino acids, and 
a short intracellular domain of approximately 10 amino acids. It  
doesn’t include identified functional domains or enzymatic 
activities. It uses other proteins, such as C -type lectin-l ike receptor-
2 (CLEC-2), heat shock protein A9 (HSPA9), CD44, galectin 8, 
chemokine (C-C motif) l igand 21 (CCL21), ezrin,  moesin,  protein 
kinase A (PKA) and cyclin dependent kinase 5 (CDK5), to change 
the  cell activity.  These proteins interact with podoplanin to direct  
tumour cell migration, invasion and metastasis 
(4 7 -4 9 )
.  
 
 Martin-Villar  et  al .  (2009) using northern blotting techniques,  
two isoforms of podoplanin have been discovered. The podoplanin 
gene comprises of 34.4 kb and 8 exons. They possibly resemble a 
product of al ternative splicing, but the biological importance of this 
study is still  to be clarified 
(5 0 )
.  A tumour promoter including Src,  
TPA and RAS encourages the podoplanin expression. For instance, 
to induce expression of podoplanin to encourage tumour cell  
motility,  the Src tyrosine kinase uses the focal adhesion adaptor 
protein Cas/BCAR1. Podoplanin expression is enhanced on th e 
transcription level such as alternative splicing, numerous initiation 
sites, and polyadenylation and on the post -translational level due to 
podoplanin calpain-mediated proteolysis 
(5 1 ,  5 2 )
.  
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Podoplanin and cancer  
 Expression of podoplanin is induced by several tumour 
promoters and can be seen in numerous forms of cancer. High clonal 
expansion capacity is a characteristic feature of tumour init iating 
cells (TIC) and podoplanin is  a TIC marker for human squamous 
cell carcinoma 
(5 3 )
.  Furthermore, the occurrence of large colony 
formation by podoplanin-positive cells is  reduced by treatment with 
a Rho-associated coiled-coil kinase (ROCK) inhibitor, while no 
difference was found in single podoplanin -negative cells 
(3 0 )
.  
 
 Podoplanin is  considered as a marker of lymphatic vessel  
endothelium. Podoplanin-positive cell forms were exposed to be 
concurrently positive for Prox1 and VEGFR -3. It appears that  
VEGF-C increases podoplanin expression through Prox1, which is a 
major regulator gene of lymphatic vessel development inducing 
LECs differentiation from lymphatic progenitor cells in embryonic 
veins 
(5 4 )
.  As well as,  expression of podoplanin was found to be 
high in dermal LECs by IL-3.The significant function of podoplanin 
in lymphatic vessel development has been done by trials conducted 
with podoplanin-deficient mice which die at  birth due to respiratory 
failure by irregular alveolar sac growth because of the absence of 
expression of podoplanin in alveolar type -1 cells 
(5 5 ,  5 6 )
.  
 
C-type lectin-like receptor-2 (CLEC-2) was discovered on human 
platelets as the first  podoplanin receptor whic h is vital  for platelet  
aggregating properties of podoplanin 
(5 7 )
.  It  was found that tumour 
cells encourage platelet aggregation which protects cancer cells 
from sheer stress and host  immunological defense. This mechanism 
may result  in increased tumour development and improved 
metastatic potential of the tumours 
(5 8 ,  5 9 )
.   
 
 Acton et al. (2012) found podoplanin as an inducer of 
dendritic  cell (DC) migration through interaction with its CLEC -2 
protein receptor.  Interaction of podoplanin expressed on fibroblastic 
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reticular cells (FRCs) and LECs with CLEC -2 on DCs caused 
improved migratory potential  of the latter. As well as,  this 
phenomenon can be significant for the migration of cancer cells 
along the lymphatic networks while the neo -expression of CLEC-2 
in a human A375 melanoma cell line caused protrusion formation in 
the contact of the CLEC-2 over-expressing A375 melanoma cell l ine 
with podoplanin expressing FRCs 
(6 0 ,  6 1 )
.  
 
Podoplanin expression and oral cancer  
 Podoplanin is expressed in several types of cancer. Oral 
cancer exemplifies the utility of podoplanin expression as a cancer 
biomarker. Podoplanin expression increases oral squamous cell 
carcinoma cell  migration, which can lead to increased metastasis
(3 0 )
.  
 
 Yuan et al. (2006)  investigated a study to examine the 
function of podoplanin in head and neck squamous cell carcinoma 
(HNSCC) in 35 cases including 16 oral tumours  and 19 hypo-
pharyngeal tumours and other group of 60 cases with oral tongue 
cancer by immunohistochemistry and found out associations 
between the podoplanin expression status and clinical and 
pathological  features of patients such as survival rate.  They f ound 
that podoplanin wasn’t expressed in normal oral epithelial cells but 
was seen in some hyperplastic and dysplastic lesions. Increased 
podoplanin expression was found in 57% of the 35 tumours and was 
more common in tumours with lymph node metastasis,  es pecially for 
oral tumours. Among 60 oral  tongue cancers,  increased podoplanin 
expression was found in 60%. Patients whose tumours expressed 
increased levels of podoplanin had a statistically significantly 
superior rate of lymph node metastasis (P<0.0001). Patients with 
lymph node metastasis and increased-level podoplanin displayed the 
shortest disease-specific survival as compared to other patients.  
Researchers concluded that  podoplanin play a role in oral 
tumourigenesis and may offer as a predictor for lym ph node 
metastasis and poor clinical consequence 
(6 2 )
.  
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 Kawaguchi et al . (2008)  conducted a study to assess the role 
of podoplanin in diagnosing of oral cancer in 150 oral  leukoplakia  
(OPL) patients.  They found that  37% of patients showed podoplanin 
expression in the basal and suprabasal  layers and were categorized 
as podoplanin posit ive. Positive result  for podoplanin was more 
common in elderly cases, females, and dysplastic lesions. OPL 
patients that were positivity for podoplanin had significantly 
increased the incidence of oral  cancer as compared to OPL patients 
with podoplanin negative 
(3 5 )
.   
 
 Funayama et al.  (2010)  conducted to evaluate the podoplanin 
expression (D2-40) in pre-cancerous lesions,  and assessed the 
immunohistochemical studies of podoplanin in oral  squamous 
epithelial lesions. The population of the study was 298 cases with 
squamous cell  carcinoma (SCC), carcinoma in situ (CIS), epithelial 
dysplasia, and hyperplastic and normal epithelial lesions by 
immunohistochemistry with D2-40. The result showed that 
positivity for podoplanin in normal or hyperplastic epithelia was 
none, whereas all of the CIS and SCC patients marked positive.  
Approximately twenty-eight percent of the mild dysplasia patients 
and 80 percent of moderate dysplasia patients exposed grade -I 
positive reactions occurred merely in the first  layer. Grade -II 
reactions occurred up to 4
t h
 layer were observed in 4% of moderate 
dysplasia patients, 39% of CIS patients, and 10% of SCC patients. 
Grade-III reactions occurred up to 5
t h
 layer and reactions were seen 
in 47% of CIS patients and 87% of SCC patients.  Researchers 
finalized that  the correlation between the present histological  
categorization and podoplanin grade was statist ically significant.  
Expression podoplanin is recognized to be associated with the 
acuteness of oral pre-cancerous lesions 
(3 3 )
.  
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 Kreppel et al (2010)  conducted to examine the effect  of 
expression of podoplanin on prognosis and metastatic lymphatic 
spread in oral  squamous cell  carcinoma (OSCC) patients with 
immunohistochemistry. They studied relationships between the level 
of podoplanin expression and different clinicopathologic 
parameters.  In 84% of patients, podoplanin was expressed on the 
tumour cells.  24% of patients exposed increased levels of 
expression. The five year overall  survival rate 31% for patients with 
increased levels of podoplanin expression was significantly lesser 
as compared to 93% and 65% for patients with decreased and 
moderate podoplanin expression respectively.  There was a 
correlation between the expression of podoplanin and the frequency 
of cervical lymph node metastases.  Cervical lymph node metastases 
were observed in 79 percent patients with increased expression of 
podoplanin, while only 22% of patients with decreased expression 
of podoplanin had metastases (p< 0.001) 
(6 3 )
.   
 
 Margaritescu et al. (2010)  reported that  expression of 
podoplanin was very low in basal  cells, particularly in resection 
margins of OSCC patients grown in the lower lip areas. 
Nevertheless, a highly variable D2 -40 expression in tumour-free 
resection margins related with hyperplastic or dysplastic lesions 
was recognized.  Additionally,  expression of podoplanin also 
developed to the basal layer of the lower lip skin appendages, the 
myoepithelial cells  of acini and ducts of minor salivary glands, and 
other parts from the oral cavity 
(6 4 )
.   
 
 Shi et al.  (2010) investigated to establish protein expression 
of podoplanin and ATP-binding cassette,  G2 subfamily (ABCG2) in 
oral lichen planus (OLP) patients and assess their use as biomarkers 
for OLP malignant transformation complication. In 120 patients, 
110 with untransformed OLP and 9 with malignant transformed OLP 
(mean follow-up of 5.1 years).  They found that  podoplanin 
expression was seen  in 43.6% patients of untransformed OLP and in 
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88.9% of patients of transformed OLP. ABCG2 expression was 
observed in 20.9% of patients of untransformed OLP and in 66.7% 
of patients of transformed OLP. The risk of OLP malignant 
transformation was significantly greater with co-expression of 
podoplanin and ABCG2 as compared to without co -expression of 
podoplanin and ABCG2. This study concluded that  since 
expressions of podoplanin and ABCG2 in OLP were considerably 
associated with malignant transformation risk ,  therefore, podoplanin 
and ABCG2 may be utilized as biomarkers for risk assessment of 
oral malignant transformation in OLP patients 
(6 5 )
.   
 
 Huber et al . (2011)  targeted to evaluate the relationship 
between expression of podoplanin in the primary tumour by 
immunohistochemistry using tissue microarrays and occurrence of 
metastases in the sentinel lymph node (SLN) of patients with early 
head and neck squamous cell carcinoma (HNSCC) of the oral cavity 
and oropharynx. Expression of podoplanin was computed by the 
intensity reactivit y score and classified into expression and non -
expression. SLN assessment displayed occult  metastasis in 37.5% of 
cases. 24.2% of cases of primary HNSCC exposed expression of 
podoplanin. Expression of podoplanin associated significantly with 
SLN metastasis  and remained a considerable predictor for lymph 
node status even after controll ing for tumour stage. As a predictive 
marker for SLN metastasis, though, expression of podoplanin gained 
a sensit ivity of an only 36% and a specificity of 83%.  Podoplanin 
expression is related with metastasis to lymph nodes in vivo. 
podoplanin immunohistochemistry in early HNSCC of the oral 
cavity and oropharynx may aid to choose patients for the SLN 
assessment and to find patients with high risk for presence of occult 
lymph node metastasis in the neck 
(6 6 )
.  
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 Shimamura et al. (2011)  evaluated the podoplanin and fascin  
expression in oral dysplasia and carcinoma in situ (CIS).  Expression 
of podoplanin was scored into 5 previously recognized 
classifications and expression of fascin was scored into 4 original  
classifications. The immunostaining scores for podoplanin and 
fascin were significantly greater in CIS and dysplasia as compared 
to benign disease (p=0.00036 and 0.0011). In all  invasive SCC 
patients, podoplanin was expressed in the cytoplasm and membrane 
of the tumour cells. This study concluded that  it  would be usefu l for 
developing the diagnostic accuracy of oral dysplasia and CIS by 
evaluating the expression of podoplanin and expression of fascin 
immunohistochemically 
(6 7 )
.   
 
 Bartuli et al. (2012)  demonstrated that  podoplanin  expression 
raises in the early stages of tumourigenesis and i t appears to be 
related with a greater risk of head and neck cancer. While in SCC, 
expression of podoplanin decreases at the time of tumour 
development. These data help a function for expression  of 
podoplanin in the beginning but not in the development of cancer.  
Authors concluded that podoplanin is concerned in oral oncogenesis 
and can be a forecaster for lymph node metastasis in asymptomatic 
patients. Histology and podoplanin analysis can be ve ry helpful to 
find the risk of growth, invasion and metastatic progression of a 
tumour in patients with oral cancer 
(6 8 )
.  
 
 de Sousa et al  (2012)  demonstrated that  majority cases with 
nodal involvement offered a high peritumoural  LVD. Moreover, a 
strong relationship of LVD with size and location of primary 
tumours could also be recognized. MVD was statistically related 
with metastasis, and a significant relationship between the 
lymphangiogenic factors and the vessels density in th e intra-
tumoural areas was also found. The well -multiplied tumours didn't 
express podoplanin.  LVD and MVD were greater in metastatic 
lymph nodes as compared in non-metastatic lymph nodes. The 
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developed vascular system in metastatic lymph nodes emphasizes 
the earlier reports of lymphangiogenesis occurrence in lymph nodes.  
Additionally,  the podoplanin expression by many undifferentiated 
tumour cells recommends that this protein could be a marker of 
tumour aggressiveness 
(6 9 )
.  
 
  Feng et al  (2012)  found the expression of podoplanin  and 
ABCG2 was 44.1% and 61.8% respectively,  and multivariate 
analysis showed that  expression pattern of podoplanin and ABCG2 
was related with 6.31-fold and 14.39-fold increased the risk of 
transformation, respectively.  This study concluded that  the 
podoplanin and ABCG2 expression were related with oral  cancer 
progression, recommending that podoplanin and ABCG2 may be 
useful forecasters for assessing oral  cancer risk 
(7 0 )
.   
 
 Kreppel et al  (2012)  evaluated whether expression pattern of 
podoplanin in pre-treatment biopsies could provide as a biomarker 
to find the risk of malignant transformation oral leukoplakia 
patients by immunohistochemistry.  They found increased 
podoplanin expression pattern in pre -treatment biopsies was related 
with malignant transformation (p= 0.003) and rising SIN-
classification (p=0.009). The five-year OCFS rate reduced from 100 
percent for patients with no expression pattern of podoplanin to 
41.7% for patients with the maximum level of expression pattern of 
podoplanin 
(7 1 )
.   
 
 Almeida et al. (2013)  performed a study to assess the clinical 
significance of expression pattern of podoplanin and vascular 
endothelial growth factor-C (VEGF-C) in well-differentiated OSCC. 
The result  showed that  strong expression of podoplanin was related 
with male (p=0.037) and with early clinical  stage (1 -2) (p=0.027). 
Strong expression of podoplanin was more often established in 
patients underwent perineural  infiltration. This study concluded that 
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the strong expression pattern of podoplanin and VEGF -C by 
malignant cells is related with perineural  invasion in OSCCs 
(7 2 )
.   
 
 de Vicente et al . (2013)  observed that  38% of cases were 
categorized as podoplanin -positive,  and the remaining 62% lesions 
were as podoplanin-negative. The podoplanin expression was 
associated with the grade of dysplasia (p<0.0005), and with the risk 
of development of oral cancer  (p<0.0005). This study concluded that 
podoplanin could be a useful biomarker for risk assessment of 
malignant transformation in OPL along with histological 
evaluation
(7 3 )
.   
 
 Chandra et al. (2014)  investigated the function of podoplanin  
in malignant transformation of potentially malignant oral  lesions 
(PMOLs) and elucidated the prognostic and clinical significance of 
both LVD and MVD in PMOLs in development of oral  cancer. In 
this study, LVD is referred as of podoplanin detected positive  
lymphatic vessels and MVD as the density of CD -31 positive micro-
vessels.  They found that  LVD is a more valuable tool as compared 
to MVD. Authors concluded that  podoplanin is contributed in 
malignant transformation to oral cancer in PMOLs patients and can  
be a predictor for lymph node metastasis in oral cancer cases 
(7 4 )
.  
 
 Cirligeriu et al. (2014)  found out expression of podoplanin in 
tumour cells of lip, oral cavity,  tongue and pharynx SCCs, together 
with lymphatic vessels distribution, morphology, density and their 
effect on tumour progression. Estimation of podoplanin by D2 -40 
immunohistochemistry assessment on 56 patients of oral cancers 
exposed two different expression patterns in tumour cells based on 
their site.  Peri -tumour and intra-tumour lymphatic vessels density,  
morphology and distribution were associated with lymph node status 
but not with tumour stage. The maximum number of lymphatic 
vessels was found in grade-III SCCs. Dual expression of podoplanin 
in tumour cells and lymphatics with particular patterns associated 
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with histopathology and lymph node status in oral cancer,  exhibiting 
the molecular basis for assessing podoplanin as a potential target  
for anti  D2-40 antibody based treatment 
(4 0 )
.   
 
 Garcia et al.  (2014)  aimed to assess the relationship between 
expression of podoplanin and ezrin by invasive tumour front cells in 
the lip cancer. 48 SCCs arising in the inferior lip were 
immunehistochemically evaluated for the membranous and 
cytoplasmic expressions of podopl anin and ezrin in peripheral  and 
central  areas of the tumour front. The relationship between the 
membranous and cytoplasmic expression of podoplanin and ezrin by 
malignant cells was assessed by chi -square test and Spearman's 
correlation coefficient with a significance level of 5% for both 
assessments. The results found that a strong membranous and 
cytoplasmic podoplanin expression by peripheral cells  of the 
invasive tumour front, with no expression of this protein by central  
cells. A statist ically significant variation was established between 
the podoplanin expression in peripheral  and central tumour cells 
(p<0,001).  This study concluded that  the tumour cells in the 
invasive front tumour expressed strongly both podoplanin 
(membranous and cytoplasmic) as cyto plasmic ezrin and it  
recommends an involvement of these proteins in the process of 
invasion in lip cancer 
(7 5 )
.   
 
 Inoue et al. (2014) assessed paraffin-embedded tissue 
specimens of 69 primary and 29 corresponding metastatic lesions by 
using antibodies against  podoplanin and α -SMA. Podoplanin 
positive stromal fibroblasts were detected in 73.9 % of the 69 
primary OSCCs and 82.8 % of the 29 lymph nodes metastases. α -
SMA immunoreactivity was found in 56.5 % of the primaries and 
82.8 % of the metastases. Further evaluation exposed that 74.5 % of 
the primary lesions and 95.8 % of the metasta ses with podoplanin 
positivity were also positive for α -SMA. Moreover, the intensity of 
α-SMA immunoreactivity raised as that of podoplanin became 
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stronger. Podoplanin-positive CAFs are considered to be 
myofibroblasts that  may involve in the development of  oral 
cancer
(7 6 )
.   
 
 Logeswari et al .  (2014)  investigated to evaluate the 
podoplanin expression in OSCC, leukoplakia and normal oral  t issues 
and to find its use as a biomarker. They found that the absence of 
expression of podoplanin in the epithelium of all the oral samples 
(Group 1). Positive podoplanin expression observed in 59.4% 
patients of leukoplakia as Group 2 and 82% patients of OSCCs as 
Group 3.  The podoplanin expression amongst different groups was 
highly significant. This study concluded that  the podoplanin may be 
considered as a forecaster in evaluating malignant transformation  of 
pre-malignancies and prognosis of oral malignancy. Certainly,  it  is 
thought that podoplanin might play a role in tumour development 
while correct  mechanism is not completely explained. Advance 
studies are needed to know its precise pathophysiology 
(7 7 )
.   
 
 Swain et al . (2014)  investigated a review study that 
summarizes the relationship of over -expression of podoplanin in 
oral potentially malignant disease and oral  cancer with special  
prominence on its putative role in carcinogenesis and also its  
potential use in targeted treatment. Podoplanin,  an important 
molecule in the signaling pathway contributed in progression of 
epithelial  dysplasia-carcinoma sequence, can act as a good 
forecaster in evaluating risk of cancer growth in potential  malignant 
diseases of oral  cavity.  With a familiar role in encouraging cancer 
cell migration and metastasis along with its specifici ty in assessing 
lymphovascular invasion, podoplanin can be projected as a new 
diagnostic and prognostic biomarker for head and neck SCC 
(7 8 )
.   
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 Ochoa-Alvarez et al. (2015)  targeted to study that how a 
monoclonal antibody (NZ-1) and lectin (MASL) that target  
podoplanin affect  human OSCC cell motility and viabil ity. Both 
testing agents blocked the migration of podoplanin expressing 
OSCC cells at nanomolar concentrations prior to blocking the cell  
viability at micromolar concentrations. Moreover,  both testing 
agents encourage mitochondrial  membrane permeability transition to 
destroy OSCC cells that express podoplanin by caspase independent 
nonapoptotic necrosis. Additionally, MASL showed an amazingly 
vigorous skil l to target podoplanin on OSCC cells within minutes of 
exposure, and significantly blocked human OSCC dissemination in 
zebrafish embryos. This study concluded that  human OSCC cells 
produced tumours that expressed podoplanin in mice, and induced 
podoplanin expression in infiltrating host murine CAFs. 
Collectively,  these studies suggest that antibodies and lectins may 
be utilized to fight OSCC and other type of cancers that express 
podoplanin 
(7 9 )
.  
 
 Parhar et al. (2015) found that normal epithelium exposed 
negligible podoplanin expression, whereas the expression expanded 
significantly at the basal  layer and the suprabasal  layer or above at 
one or multiple regions in potentially malignant lesions. Podoplanin 
expression in OSCC displayed two various patterns include diffuse 
and focal.  A statistically significant rise in average LVD was found 
from normal epithelium to OPMLs (P<0.001) and to OSCC 
(P<0.022) whereas a non-significant rise was observed (P<0.594) 
between OPMLs and OSCC. On the whole, no significant 
relationship was seen between D2-40 epithelial  positivity and LVD 
(P=0.122) 
(8 0 )
.   
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 Patil et al.  (2015)  found that  statistically highly significant 
rise of the expression of podoplanin from mild to severe dysplasia 
and from well  to poorly differentiate OSCC by one -way ANOVA 
test  (P < 0.01).  Highly significant difference was observed between 
grades of mild to moderate dysplasia, moderate to severe dysplasia, 
well to poorly differentiated OSCC, and moderately to poorly 
differentiated OSCC by Turkey HSD test (P < 0.01). Authors 
concluded that podoplanin can be uti lized as a biomarker for 
premature oral carcinogenesis and for malignant transformation risk 
assessment of pre-malignant lesions and as a tumour development 
biomarker for higher grades of OSCC 
(8 1 )
.   
 
 Prasad et al.  (2015)  found that 27 patients of SCC displayed 
expression of podoplanin  and there is  no expression in remaining 3 
patients. In OSCC, 7 patients showed weak expression offered 
immunoreactive score (IRS) 0 to 3,  fifteen patients showed 
moderate expression offered IRS Score 4 to 7 and five patients 
showed high expression offered  IRS Score greater than 8. The 
evaluation of expression of podoplanin in the cytoplasm, the 
membrane and both (cytoplasm and membrane) of tumour cells 
exposed overall high positivity in the cytoplasmic followed by both 
and the membrane 
(8 2 )
.   
 
 Sgaramella et al.  (2015)  investigated to evaluate the 
expression of podoplanin  using immunohistochemistry.  The mRNA 
levels were assessed in twenty-seven patients of tongue SCC with 
adjacent clinically tumour-free tongue t issue and fourteen tongue 
samples were collected from healthy patients. Increased podoplanin 
levels were found in  tumours compared to both normal tongue and 
clinically normal tongue in the tumour vicinity.  This study 
concluded that  podoplanin levels in primary tongue SCCs aren't 
related with lymph node metastases. Though, tongue SCCs emerging 
in young patients are more probable to express high podoplanin 
levels as compared to tongue SCCs that emerge in the older 
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patients. The study recommends that podoplanin has a characteristic 
function in young patients, who are recognized to have a poor 
diagnosis, these patients ma y benefit from podoplanin inhibitory 
treatments (83).   
 
 Habiba et al.  (2016)  revealed that HuR and podoplanin 
expression was associated with a 2.93‑ fold and 2.06‑ fold increase 
in risk of malignant transformation, respectively.  The risk of OPL 
malignant transformation was significantly increased with the co -
expression of HuR and podoplanin compared with the histological  
grading. Researchers concluded that the expres sion of HuR and 
podoplanin correlated with malignant transformation and 
recommends that  the proteins may be used as biomarkers to identify 
OPL patients with a higher risk of developing cancer 
(8 4 )
.  
 
 Ugorski  et al.  (2016)  described podoplanin is a tiny 
membrane glycoprotein with a huge number of O -glycoside chains 
and consequently,  it  belongs to mucin -type proteins. It  can be found 
on the surface of numerous types of normal cells emerging from 
various germ layers. It is found mainly on the endothelium of 
lymphatic vessels, type I pneumocytes and glomerular podocytes.  
High levels of podoplanin or its neo -expression have been 
established in several  types of human carcinomas, but it  is 
particularly widespread in SCCs, includes cervical,  larynx, oral 
cavity,  and lung and skin cancer. This tiny sialomucin is also found 
on the surface of CAFs in lung adenocarcinomas, and also in breast  
and pancreatic tumours. Little is  recognized about the biological  
function of podoplanin. However, research done on mice with a 
knock-out gene of this glycoprotein displays that  the presence of 
podoplanin determines normal development of lungs, the lymphatic 
system and heart . Podoplanin on carcinogenesis and CAFs appears 
to play a significant role in the growth and development of different 
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cancers.  However,  i ts role in these processes is  both unclear and 
controversial  
(8 5 )
.   
 
 Deepa et al . (2017)  evaluated the podoplanin expression in 
oral leukoplakia,  oral  sub-mucous fibrosis and OSCC with that  in 
normal buccal mucosa by immunohistochemistry with D2-40. The 
expression of podoplanin was graded from grade 0 -4. This study 
found that  statistically there was a significant increase of the grades 
of expression of podoplanin in OSCC as 100%, oral sub -mucous 
fibrosis as 90% and oral leukoplakia as 65% when compared to that  
in normal mucosa as 35%. Expression of podoplanin increased with 
decrease in grades of differentiation in OSCC. Expression of 
podoplanin in the samples of oral sub -mucous fibrosis was superior 
to that  in oral leukoplakia.  This study concluded that  the assessment 
of expression of podoplanin in the epithelial cells  of oral dysplastic 
lesions may offer useful information to find their malignant 
transformation risk 
( 8 6 )
.   
 
 Liu et al. (2017)  performed a study to evaluate the expression 
pattern of ABCG2 and podoplanin in OSCC tissues and 
corresponding cervical  lymph node, and assess the diagnostic value 
of ABCG2 and podoplanin in OSCC for carcinogenesis, histological  
stage and clinical  diagnosis. ABCG2 displayed a mixed membranous 
and cytoplasmic pattern of staining in certain areas of stratum 
corneum and the center of well -differentiated tumour, whereas 
merely expressed in cytoplasm of poorly differentiated tumour.  
Podoplanin exposed strong staining in LV endothelia, the periphery 
of well-differentiated cancer and tumour stromal fibroblasts 
encompassing tumour nests. The ABCG2 expression, part icularly 
cytoplasmic ABCG2, and podoplanin protein exposed significantly 
superior tendency to lymph node metastasis (P<0.05). At the same 
time, podoplanin positive rate raised with the reducing degree of 
histological differentiation (P<0.05 ).  ABCG2 and podoplanin 
expression pattern is  associated with OSCC lymph node metastasis. 
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Authors suggested that  cytoplasmic ABCG2 with podoplanin have 
clinical prospective in stable molecule diagnosis for OSCC 
(8 7 )
.   
 
 Gissi  et al.  (2018) conducted a study to evaluate a possible 
relation between altered podoplanin expression and dysplasia by 
immunohistochemistry and biomarkers such as p53 and Ki67 in 40 
OPL patients.  32 cases didn’t  expose dysplasia, while 8 lesions 
presented with dysplasia.  They found that al l three biomarkers were 
positive in 7 of 8 dysplastic oral lesions. Among the patients 
without dysplasia,  Ki67 and p53 exposed positivity in 21 and 10 
samples respectively, whereas positivity for podoplanin was found 
merely in a patient 
(8 8 )
.  
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MATERIALS AND METHODS 
 
Materials  
Collection of samples  
 
 The present study is comprised of 20 patients,  diagnosed with 
oral squamous cell  carcinoma (OSCC). As controls, we used 5 
normal tissues (alveolar mucosa) samples. Tumour  as well as normal 
samples and clinical  data were collected from Madha Dental College 
and Hospitals (Department of Oral Pathology and Microbiology). 
For the collection of samples, an informed written consent was 
taken from all patients and controls. A ques tionnaire was made for 
retrieving the demographic information about subjects such as age, 
gender, family history of cancer as well as tobacco chewing, 
smoking and alcohol habits.  
 
Immunohistochemistry (IHC)  
 In the present study we used immunohistochemistry (IHC) 
staining method to detect  expression of Podoplanin within the cell.  
Primary antibody used in this study was mouse monoclonal antibody 
(clone D2-40) and immunohistochemical staining was done by using 
the PolyExcel HRP/DAB Detection System. IHC is based on 
antibody-antigen reaction. Total twenty tumour t issue and five 
normal tissue samples were selected for IHC. Specific monoclonal 
antibody raised against podoplanin proteins in the cell is used as the 
primary antibody.  Furthermore antibody raised against the 
podoplanin primary antibody was used as the secondary antibody. 
On addition to tissue sections,  the primary antibody attaches to the 
specific cell protein. Then secondary antibody is added, which 
attaches to the primary antibody.  Then, the enzyme attached to the 
secondary antibody reacts with the chromogen to produce colour.  
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Materials required  
1.  PolyExcel detection kit (PathnSitu’s)  
2.  Xylene 
3.  Positive charged slides  
4.  Citrate buffer (Antigen retrieval buffers)  
5.  Immuno wash buffer  
 
Graded series of alcohol:  Graded series of alcohol (50%, 70%, and 
90% ethanol,  v/v) were prepared by diluting ethanol with the 
appropriate volume of double distilled water. For absolute (100%) 
alcohol, ethanol was used directly from the bottle as supplied by 
manufacturer without further dilution.  
 
Citrate Buffer (pH 6.0):  This buffer consisted of the following 
components:  
1.  Citric acid-100 mM  
2.  Sodium citrate dehydrate -100 mM  
3.  NaOH solution -5N: This was prepared by dissolving 200 g of 
NaOH in 1 L of double distilled water  
 
  To prepare 100 mM citric acid stock solution 1.92 g of 
citric acid,  anhydrous was dissolved in 100 ml of double distilled 
water. The stock solution of 100 mM sodium citrate dehydrate was 
prepared by mixing 14.7 g of sodium citrate dehydrate in 500 ml of 
double distil led water. In order to prepare the working solution of 
citrate buffer, 9 ml of 100 mM citric acid and 41 ml of 100 mM 
sodium citrate dehydrate were mixed properly and the final  volume 
was adjusted to 500 ml with double distilled water.  The pH was 
adjusted using 5N NaOH solution.  
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Phosphate Buffered Saline (PBS, pH 7.4):  This buffer consisted of 
the following components  
i)  NaCl…………….140 mM  
i i)  KCl……... .. . . . . . . . . . . . .2 mM  
i ii)  Na2HPO4……….10 mM  
iv)  KH2PO4………….1 mM  
 
 The above chemicals were dissolved in the required volume of 
double distilled water.  The pH recorded was approximately 7.4,  and 
the pH was not adjusted further. This buffer was stored at room 
temperature (RT).  
 
Blocking solution:  This solution consisted of the following 
components:  
i)  BSA (3% w/v)  
ii)  Phosphate buffered saline (PBS, pH 7.4)  
iii)  The blocking solution was prepared by dissolving 3 g of BSA 
in 100 ml of PBS buffer.  The mixture was stored refrigerated 
at 4 °C refrigerated without further agitation.  
 
Tris Buffered Saline (TBS, pH 7.5):  
 This buffer consisted of the following components  
i)  Tris-Cl (pH 7.5)………..10 mM  
i i)  NaCl…………………..500 mM  
 
 To prepare 100 ml of Tris -Cl buffer,  0.12 g of Tris  base was 
dissolved in 100 ml of double distilled water, the pH was adjusted 
to 7.5 with concentrated HCl, and the final volume was adjusted to 
100 ml with double distilled water. TBS buffer was prepared by 
dissolving 2.9 g of NaCl in 100 ml of Tris -Cl buffer. The buffer was 
stored at RT.  
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Tris Buffered Saline solution (TTBS):  
 This solution consisted of 0.05 % Tween -20 (v/v) in TBS 
buffer. To prepare 1 L of TTBS solution, 50 μl of Tween -20 was 
dissolved in 1 L of TBS buffer by continuous stirring.  
 
 
Primary antibody solution:  
 Primary antibody (D2-40) to Podoplanin was diluted in 
antibody diluent, with 1% bovine serum albumin (BSA) and 0.05% 
sodium azide (NaN3) in a dilutions of 1:100.  
 
 DPX mountant 
 Pressure cooker 
 Cover sl ips  
 Microscope 
 
METHODOLOGY  
 
Fixation 
 Proper fixation is key for the success of 
immunohistochemistry.10% neutral buffered formalin (NBF) was 
used. Biopsy tissue samples have been received in 10% formalin and 
fixed i t 18-24 hours.  After fixation, the t issue block were e mbedded 
in paraffin,  then cut in a microtome to the desired thickness and 
affixed onto the slide.  
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Paraffin Tissue processing  
1.  After tissue fixation, rinse fixed tissue with PBS buffer unti l 
fixative is totally removed.  
2.  Then dehydrated tissue using ethanol in the following order:  
 
Solution Incubation time 
50% Ethanol  10 min 
70% Ethanol  10 min 
80% Ethanol  10 min 
95% Ethanol  10 min 
100% Ethanol  10 min 
100% Ethanol  10 min 
100% Ethanol  10 min 
 
3. Exchange ethanol with xylene  in the following sequence  
Solution Incubation time 
2:1 Ethanol: Xylene  10-15 min 
1:1 Ethanol: Xylene  10-15 min 
1:2 Ethanol: Xylene  10-15 min 
100% Xylene 10-15 min 
100% Xylene 10-15 min 
100% Xylene 10-15 min 
 
4.  Exchange xylene with paraffin.  The following steps are done in a 
vacuum oven set at  54-58°C.  
Solution Incubation time 
2:1 Xylene: Paraffin  30 min 
1:1 Xylene: Paraffin  30 min 
1:2 Xylene: Paraffin  30 min 
100% Paraffin  1-2 hrs  
100% Paraffin  1-2 hrs or overnight  
 
5.  Now the tissues were embedded in fresh paraffin and position 
tissue as desired before it  was harden  
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Sectioning of sample:  
 4 µm thickness of processed tissue samples were cut into 
section and mounted on positively charged glass slide.  
 
Deparaffinization 
 Tissue sections were deparaffinized by pressing the glass 
slides over a hot plate till  the paraffin just melts. The slides were 
immediately dipped in xylene and kept immersed for 20 min.  
 
Drying and rehydration:   
 The glass slides were blotted dry and then transferred through 
serial dilutions of ethanol, i .e.,  100% ethanol for 1 min, 90% 
ethanol for 1 min, 70% ethanol for 1 min, and 50% ethanol for 1 
min. This was followed by immersion in tap water for 2 min.  
 
Antigen retrieval  
 Formalin-fixed tissue in most of the time needs an antigen 
retrieval step before immunohistochemical staining. This retrieval 
step is required due to the formation of methylene bridges during 
fixation, which cross-link proteins and therefore  mask antigenic 
sites. We used citrate buffer as antigen retrieval solution.  
 
Heat-mediated antigen retrieval Method:  
1.  Place slides in a metal rack and then place the rack in jar 
filled with citrate buffer.  
2.  Add the appropriate antigen retrieval citrate buff er to the 
pressure cooker and then place the pressure cooker on the 
hotplate and turn it on full power.  
3.  Next put the jar containing slides in pressure cooker and 
cover the lid securely  
4.  As soon as the cooker has reached full pressure,  (in about 3 
minutes time), turn off the hotplate and placed the pressure 
cooker in an empty sink.  
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5.  Activate the pressure release valve and run cold water over 
the cooker. Once de-pressurized, opened the lid and run cold 
water into the cooker for 10 minutes.  
6.  After that continue  with the immunohistochemical staining 
protocol.  
 
Immunohistochemical staining  
 PolyExcel detection system was use with primary antibodies 
(D2-40) for the qualitative identification of antigens by light 
microscopy in normal and pathological paraffin -embedded t issues.  
PathnSitu’s PolyExcel detection system is highly sensitive, non -
biotin, micro-polymer based system which significantly reduce 
background staining. This system is based on an HRP labeled 
polymer, which is conjugated with secondary antibodies.  
 
Details of PathnSitu’sPolyExcel  detection kit supplied below:  
 
 
Staining procedure:  
1.  Block endogenous peroxide activity by incubating the samples 
for 5–10 minutes with PolyExcel H 2O2 .  
2.  Cover the tissue sections with primary antibody (D2 -40) and 
incubate for 30 min at room temperature.  
Description Pack Size Kit Contents  
PolyExcel 
HRP/DAB 
Detection  
System 
PEH2-50ml 
PolyExcel H2O2  
PolyExcel Target Binder  
PolyExcelPolyHRP 
PolyExcelStunn DAB Substrate 
Buffer  
PolyExcelStunn DAB Substrate 
Chromogen 
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3.  Then cover the t issue sections with Poly Excel Target Binder 
and incubate for 10minutes at room temperature.  
4.  Cover the tissue sections with Poly Excel Poly HRP and 
incubate for 10mins at room temperature.  
5.  Next cover the tissue sections with StunnDAB workin g 
solution and incubate it  for 5 min at  room temperature.  
Working solution was prepared by mixing 1ml of Poly Excel 
Stunn DAB Buffer and 1drop of Poly Excel Stunn DAB 
chromogen. This solution is stable for a week when stored at 
2-8C. However,  for clean and crisp results, i t  is 
recommended to use freshly prepared working solution.  
6.  Then cover the tissue sections with hematoxylin and incubate 
for 30 mins at room temperature.  
7.  Finally dehydrate slides through graded alcohols and xylenes.  
The slides were then mounted by pouring a drop of DPX over 
the section and cover slip was placed, taking care to avoid 
trapping air bubbles. Excess DPX was wiped off, and the 
slides were left to dry overnight at RT followed by for 
microscopic observation.  
 
Staining Interpretation:   
 The cellular staining pattern for anti -D2-40 is cytoplasmic 
and sometimes membranous. In OSCC, podoplanin expression was 
scored as described by Rodrigo et al . by quantity of posit ive tumour 
cells on a scale of 0 to 5 as follows 
(4 4 )
:  
 
 0 =  negative.  
 1  = less than 10%.  
 2 = more than 11% and less than 30%  
 3  = more than 31% and less than 50%.  
 4  = more than 51% and less than 80%  
 5  =  more than 80% posit ive staining.  
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The staining intensity was rated on a scale of 0 to 3  
 0 = negative,  
 1  = weak,  
 2  = moderate, and  
 3  = strong.  
 
 The raw data were then converted to a German 
Immunoreactive Score (IRS) by multiplying the quantity and 
staining intensity scores.  The scores could range from 0 to 15. An 
IRS score above the median (7 or higher) was considered high 
reactivity and 0 to 6 weak reactivity 
(4 4 )
.  
 
 Cancer risk was calculated according to the method described 
by De Vicente et al . 
(4 5 )
 and Kawaguchi et al .
(4 6 )
:   
 
Score 0-1  =  low risk or negative expression.  
Score 2 or more =  high risk or positive expression.  
 
Statistical Analysis  
 The collected information & data were compiled & analyzed 
using appropriate statistical methods. Percentage was calculated for 
the subjects with respect to their demographic variables. The 
association between podoplanin expression status from well to 
poorly differentiated OSCC was analyzed using one -way ANOVA 
test , with the help of IBM SPSS statistics 24.0.  A chi -square test  or 
Fisher exact test was used to assess the associations among 
categorical  data.  Difference in the mean value of podoplanin 
expression score in tobacco-betel quid chewers, smokers, and 
alcohol as well as the difference in the mean age among subjects 
with low and high podoplanin expression were analyzed using t -test.  
The two-tailed P-values  were calculated to signify statistical  
difference between all comparisons.  The P-value  less than 0.05 was 
considered significant. All the data were analyzed using IBM SPSS 
software version 24.0.  
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RESULTS 
 
 The detailed demographic characteristics of OSCC patients 
are depicted in Table 3.1 .  The percentage of male and female 
patients were 70% and 30% respectively ( Figure 3.1). The male:  
female ratio was 2.3:1. The mean age of the OSCC patients in our 
study was 58 years and majority of the patients belongs to age 
above 45 years at  the time of diagnosis.  The majority of the 
collected biopsy samples were buccal mucosa (65%) foll owed by 
alveolar mucosa (35%). The frequencies of tobacco and betel -quid 
chewing, smoking, and alcohol intake in OSCC patients were 75%, 
70% and 65% respectively (Figure 3.3 ).   
 
 Histologically,  35% of the OSCC was well differentiated 
(grade-I), 30% was moderately differentiated (grade-II),  25% was 
poorly differentiated (grade-III) and 10% of OSCC tumour was 
grade-IV.  
 
 
 
Figure 3.1 Percentage of male and female patients  
 
[PERCENTAG
E]
[PERCENTAG
E]
Gender
Male Female
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Table 3.1 Demographic and clinicopathological characteristics in 
the OSCC patients  
Characteristics  Frequency Percentage 
Gender  
Male 14 70 
Female 6 30 
Age  
35-44 4 20 
45-54 8 40 
≥55  8 40 
Mean ± SD (58 ± 9.04)  
Tobacco and betel-quid chewing  
Yes 15 75 
No 5 25 
Smoking  
Yes  14 70 
No  6 30 
Alcohol  
Yes 13 65 
No 7 35 
Grade  
I 5 35 
II 6 30 
III  6 25 
IV 3 10 
Site  
Buccal mucosa 13 65 
Alveolar mucosa 7 35 
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Figure 3.2 Distribution of patients according to age groups  
 
 
 
Figure 3.3 Frequencies of lifestyle habits in OSCC patients  
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Immunohistochemistry Staining Interpretation  
 Table 3.2  and Figure 3.4  summarized the podoplanin 
expression in OSCC patients.  Among the 20 tissues of OSCC cases 
analysed, 8 cases (40%) showed no detectable podoplanin 
expression (scored as 0), 6 (30%) showed podoplanin express ion 
between 31-50% (scored as 3), 5 (25%) cases showed podoplanin 
expression between 51-80% (scored as 4), and only 1 (5%) showed 
expression between 11-30% (scored as 1). Tissues with widespread 
podoplanin expression outside the basal layer may reveal clon al 
expansion and are more predisposed to the progression, based on 
that Yuan et al.,  (2006), criteria to described by tumours and 
demonstrated that tumours with scores ≥ 2 were measured as 
podoplanin posit ive 
(6 1 )
.  Thus, 12 (60%) of the studies specimens 
were categorized as podoplanin -positive and the remaining 8 (40%) 
were classified as podoplanin-negative. Based on the staining 
intensity,  tissue specimens were categorized into four groups, dark 
brown staining of cells (strong) score as 3, dark brown and weak 
staining (moderate) score as 2 and score 0 no staining. In the 
present study 35% specimens had strong staining intensity,  25% had 
moderate intensity and 40% had no staining intensity ( Figure 3.7 ).  
 
 German Immunoreactive Score (IRS) was calculated by 
multiplying quantity score and staining intensity scores (scores 
range from 0 to 15). :  Score 7 or above represent high 
immunoreactivity and score 0 to 6 represent weak reactivity 
immunoreactivity.  In our study 35% of OSCC patients had high 
immunoreactivity and 65% of patients had low reactivity.  
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Table 3.2 Podoplanin expression interpretation in OSCC patients  
 
Scoring Frequency Percentage 
Podoplanin expression score  
0 (no staining)  8 40 
1 (1-10%) 0 0 
2 (11-30%) 1 5 
3 (31-50%) 6 30 
4 (51-80%) 5 25 
Podoplanin expression status  
Positive 12 60 
Negative 8 40 
Staining intensity score  
0 8 40 
1   
2 5 25 
3 7 35 
Immunoreactive Score (IRS)  
Low 13 65 
High 7 35 
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Figure 3.4 Percentage of podoplanin  expression in OSCC patients  
 
 The associations between podoplanin expression and the 
demographic and clinicopathological  characteristics were depicted 
in Table 3.4 .  Higher levels of podoplanin  expression were observed 
in female (66.7%) compared to male, however this difference was 
not statistically significant (P  = 0.122). Higher podoplanin 
expression was found in buccal mucosa (46.1%) as compared to 
alveolar mucosa (24.3%). We also found highe r podoplanin 
expression in tobacco-betel  quid chewers (56.7%), smokers (42.9%) 
and alcohol consumers (53.9%) as compared to non -consumers. 
However, only alcohol consumptions shown statistically significant 
correlation with podoplanin expressions (P=0.044).  That is  alcohol 
consumers had significantly higher podoplanin expressions. 
Podoplanin expression significantly increased as grade increased. 
Grade-IV carcinomas exhibited significantly higher levels of 
podoplanin expression, as compared to moderately or w ell  
differentiated carcinomas (P=0.004).   
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Figure 3.5 Expression of podoplanin in OSCC :  weak reactivity 
(A=20% and B=30% staining)  
 
 
 
 
Figure 3.6 Expression of podoplanin in OSCC :  moderate reactivity 
(A=40% and B=50% staining)  
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Figure 3.7 Expression of podoplanin in OSCC :  high reactivity and 
strong staining (A=60% and B=70% staining)  
 
 
Table 3.3 Podoplanin expression score in different grades of OSCC   
Grade No. 
Mean ± 
SD 
Std. 
Error 
95% Confidence Interval 
for Mean 
Lower 
Bound 
Upper 
Bound 
I 6 0.33±0.81 0.333 -0.52 1.19 
II 5 2.40±1.34 0.600 0.73 4.07 
III  4 2.75±1.89 0.946 -0.26 5.76 
IV 5 3.00±1.73 0.775 0.85 5.15 
Overall  20 2.00±1.74 0.391 1.18 2.82 
SD= standard deviation  
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Table 3.4 Demographic and clinicopathological  characteristics of 
the OSCC patients and correlations with podoplanin expression.  
Parameters  
 
No. 
Low 
podoplanin 
Expression 
High 
podoplanin 
Expression 
p-value 
Gender  
Male 14 11 (78.6%) 3 (21.4%) 
 
Female 6 2 (33.3%) 4 (66.7%) 0.122
*
 
Age 
Mean ± SD  53.08 ± 8.18 58.43 ± 9.72 0.138
#
 
Tumour site  
Alveolar mucosa 7 6 (85.7%) 1 (24.3%)  
Buccal mucosa 13 7 (53.9%) 6 (46.1%) 0.329
*
 
Tobacco-betel quid chewing  
No 5 5 (100%) 0 (0%)  
Yes 15 8 (53.3%) 7 (56.7%) 0.114
*
 
Smoking  
No 6 5 (83.3%) 1 (16.7%)  
Yes 14 8 (47.1%) 6 (42.9%) 0.354
*
 
Alcohol  
No 7 7 (100%) 0 (0%)  
Yes 13 6 (46.1%) 7 (53.9%) 0.044
*
 
Grade  
I 6 6 (100%) 0  
II 5 5 (100%) 0  
III  4 1 (25%) 3 (75%)  
IV 5 1 (20%) 4 (80%) 0.004**  
* Fisher 's  Exact Test  (p-value) 
** Pearson Chi-Square (p-value) 
#
 t-test (p-value) 
Statist ically significant p-value (less than 0.05) indicated in bold  
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 Mean of podoplanin expression score increases with the 
increase of grade from I to IV (i.e.  from well  differentiated to 
poorly differentiated).  Overall  mean podoplanin expression score 
was 2.00 (SD=1.74).  The highest mean podoplanin expression score 
was observed in grade-IV (3.00) while lowest mean podoplanin 
expression score was found in grade -I (0.33) (Figure 3.8).  By 
applying one-way ANOVA test,  there was a  highly significant 
increase of the podoplanin expression scores from well  
differentiated to poorly differentiated OSCC samples ( Table 3.5) 
 
 
Table 3.5 Analysis of variance of podoplanin expression between 
and within different grades of OSCC  
 
ANOVA  
Podoplanin Expression score  
 
Sum of 
Squares 
DF 
Mean 
Square 
F p-value 
Between 
Groups 
24.717 3 8.239 3.961 0.027 
Within 
Groups 
33.283 16 2.080   
Total  58.000 19    
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Figure 3.8  Mean podoplanin  expression score increases with the 
increase of grading of OSCC 
 
 
Table 3.6 Comparison between mean podoplanin Expression score 
of early and late grade of OSCC.  
 
Cancer 
Grade 
N Mean 
Std. 
Deviation 
t- test           
(p-value) 
Podoplanin 
Expression 
score 
Early (I-II)  11 1.27 1.489 0.036 
Late 
(III_IV)  
9 2.89 1.691  
 
 When we compared the podoplanin expression score of early 
and late cancer grade we found a significantly higher podoplanin 
expression in later grade of OSCC as compared to early grade of 
OSCC (P=0.036).  
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Table 3.7 Mean and standard deviation of podoplanin expression 
score in tobacco chewers, smokers and alcohol consumers  
Habits  Mean ± SD t-test  (p-value) 
Tobacco   
Yes 2.27 ± 1.75 0.247 
No 1.20 ± 1.64  
Smoking   
Yes 2.36 ± 1.64 0.169 
No 1.17 ± 1.83  
Alcohol    
Yes 2.46 ± 1.76 0.109 
No 1.14 ± 1.46  
 
 The mean value of podoplanin expression score in tobacco -
betel quid chewers,  smokers, alcohol drinkers were depicted in 
Table 3.7. The meanpodoplanin expression score in tobacco-betel  
quid chewers, smokers, and alcohol drinkers were 2.27, 2.36, and 
2.46 respectively,  which were higher than non -chewers, non-smoker 
and non-alcohol drinkers. However, no significance difference of 
podoplanin expression were observed between chewers and non -
chewers, smokers and nonsmokers and between alcohol drinkers and 
non-drinkers.  
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Table 3.8 Characteristics of the OSCC patients and correlations 
with positive and negative podoplanin expression  
 
Variables  
Podoplanin 
Negative 
Podoplanin 
Positive 
p-value 
Gender    
Female 1 (12.5%) 5 (41.7%) 0.187 
Male 7 (85.5%) 7 (58.3%)  
Site    
AM 4 (50%) 3 (25%) 0.251 
BM 4 (50%) 9 (75%)  
Tobacco betel quid 
chewing 
   
No 3 (37.5%) 2 (16.7%) 0.296 
Yes 5 (62.5%) 10 (83.3%)  
Smoking    
No 4 (50%) 2 (16.7%) 0.137 
Yes 4 (50%) 10 (83.3%)  
Alcohol     
No 4 (50%) 3 (25%) 0.251 
Yes 4 (50%) 9 (75%)  
Grade    
I  5 (62.5%) 1 (8.3%) 0.081 
II 1 (12.5%) 4 (33.3%)  
III  1 (12.5%) 3 (25%)  
IV 1 (12.5%) 4 (33.3%)  
 
 The comparison between podoplanin positive and podoplanin 
negative OSCC patients were summarized in Table 3.8.  Higher 
frequency of podoplanin positive were observed in male (58.3%) 
compared to female (41.7%), however this difference was not 
statistically s ignificant (P  = 0.187). Podoplanin positive OSCC 
patients had higher smoking, tobacco chewing and alcohol habits as 
compared podoplanin negative OSCC patients.  
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DISCUSSION 
 
 Oral cancer is one of the most common malignancy worldwide 
and each year about 14 million new oral  cancer patients are 
diagnosed. The incidence ratio of oral cancer is higher in men as 
compared to women. Squamous cell  carcinoma (SSC) is the most 
common histological type of oral cancer as 90% of oral  cancers 
originate from the squamous cells
(1 )
.  The development and 
progression of oral  squamous cell carcinoma is a multifaceted 
complex disease involving environmental and genetic factors. Major 
risks associated factors with oral cancer are tobacco, betel quid and 
alcohol intake.  
 
 Higher risk of oral cancer is growth is significantly 
associated with the clonal upward expansion of anomalous cells in 
the epithelial  layers of dysplastic lesions. Therefore,  the capabili ty 
to detect  these abnormal cells expanding beyond basal layers may 
help us to detect the potential  expansion of abnormal cells during 
tumourigenesis.  Previously,  it  was shown that  phenotypically 
distinct  subset of clonogenic cells was accountable for creating 
tumours and was considered as tumour initiating cells (TICs) or 
cancer stem cells. Podoplanin is irregularly expressed in the early 
oral tumourigenesis and is recognized as a molecular marker for 
identification of TICs in squamous cell carcinoma 
(8 1 )
.  Over the past  
two decades,  in spite of the medical advancements in local control  
and the use of different combined therapies, the survival rates for 
oral cancer have not enhanced significantly. Delay in diagnosis is 
one of the major factor for low survival rate in oral cancer patients,  
hence, novel diagnostic methods of oral  cancer need to be developed 
for early detection and therapy 
(6 )
.  A better understanding of 
mechanisms leading to OSCC is needed to develop more effective 
diagnostic and therapeutic methods for oral  cancer.  
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 In our study, we found 60% of the OSCC samples with 
podoplanin-positive expression, while 40% of the cases and normal 
oral alveolar mucosa samples had podoplanin -negative. We also 
observed that there was no podoplanin expression in normal oral  
alveolar mucosa samples. Similar type of result were reported Yuan 
et al.  (2006) found 60% podoplanin expression in oral cancer 
(6 2 )
,  
Kawaguchi et al.  (2008) in his study found 37% expression of 
podoplanin in oral cancer
(3 5 )
,  Kreppel et al. (2010) reported 84% of 
the patients with podoplanin expression
(6 3 )
,  Inoue et  al.  (2014) 
reported podoplanin positive stromal fibroblasts in 73.9 % of the 
primary OSCCs
(7 6 )
.  Logeswari et al.  (2014) observed positive 
podoplanin expression in 82% patients of OSCCs
(7 7 )
,  and Parhar et 
al.  along with Patil  et  al .  also found podoplanin expression in oral  
cancer 
(4 2 ,  8 0 )
.  We found that 30% of the OSCC patients showed 
podoplanin expression between 31 -50% (scored as 3),  25% cases 
showed podoplanin expression between 51 -80% (scored as 4),  and 
only 5% showed expression between 11-30% (scored as 1).  
 
 These results indicated a higher percentage of podoplanin 
expression in OSCC. Tissues with widespread podoplanin 
expression outside the basal layer may reveal clonal expansion and 
are more predisposed to the OSCC progression
(6 2 )
.  Latest studies 
have revealed that  podoplanin intercedes a cellular signaling 
pathway leading to directional and combined cell migration as well 
as increased expression of podoplanin promotes intense alteration of 
cellular morphology. Introduction of podoplanin expression 
enhanced multiple alterations of intracellular pathways, 
consequences in the modulation of GTPase activities (Rho family)  
and initiate the phosphorylation of R adixin,  Ezrin,  and Moesin 
proteins,  along with the reorganization of the actin cytoskeleton, 
which results in cell  migration and invasion. Therefore,             
podoplanin associates with higher occurrence of metastasis in early 
OSCC
(7 3 ,8 1 )
.  Latest  studies have revealed that the  podoplanin 
expression is also associated with the malignant transformation in a 
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grade dependent manner 
(3 5 )
.  Prior studies also demonstrated that 
podoplanin expression and premalignant lesions at  suprabasal layer 
may signify tumour initiati ng cells (TICs) 
(4 2 ,7 6 )
.  Earlier studies 
reported, certain mild dysplastic lesions displaying elevated 
expression of podoplanin beyond basal layer.  
 
 Early presentations and precancerous stages of oral cancer are 
often observed as red or white mucosal lesions and defined as oral  
erythroplakia (red) or oral  leukoplakia (white), respectively.  
Subsequently, precancerous lesions advance from hyperplasia to 
dysplasia and then carcinoma in situ before developing into invasive 
oral  malignant neoplasia
(2 )
.  According to Border 's  system of 
grading, tumours were graded on the basis of the degree of 
differentiation and keratinization of tumour cells into four groups,  
namely grade-I (Well differentiated tumours), grade -I (Moderately 
differentiated tumours),  grade -III (poorly differentiated tumours) 
and grade-IV (Anaplastic tumours).  
 
 Previous studies have reported that podoplanin expression 
increases from well  differentiated OSCC to poorly differentiated 
OSCC. In our study, we observed grade-IV OSCC (poorly 
differentiated) exhibiting significantly higher levels of podoplanin 
expression, as compared to moderately or well differentiated OSCC 
(P=0.004).  This result supports the finding of previous studies that 
demonstrated increased expression of podoplanin with the 
increasing grades of OSCC 
(6 4 ,  8 9 )
.  These results were in contrast to 
the study of Rodrigo et al . ,  who found very high podoplanin 
expression in well  differentiated squamous cell  carcinoma when 
compared to poorly differentiated squamous cell carcinoma 
(4 4 )
.  
Higher podoplanin expressing cells were mostly si tuated at  the basal 
layer, adjacent to the neighboring stromal cells, at the invasive 
front. The podoplanin expression increases from well differentiated 
to poorly differentiated OSCC 
(4 2 )
.   
 
Discussion 
 
 58 
 
 Generally podoplanin expression exhibits two different 
patterns in the tumour cells,  one is diffused expression and the other 
one is focal  expression. Focal expression occurs mainly in 
proliferating margins with no expression in the central  areas of  the 
tumour cells. The spreading pattern of podoplanin was witnessed 
within the tumour cells of well differentiated squamous cell  
carcinoma. Furthermore, podoplanin positive tumour nests seem to 
be more confined to the periphery while the central area of t umour 
nests looked negative 
(4 1 ,  9 0 )
.  Majority of the differentiated 
squamous cell carcinoma disclosed a diffuse pattern, whereas others 
showed focal expression. On the other hand all the cases of poorly 
differentiated squamous cell  carcinoma exhibited diffuse 
expression. This diffuse expression of  podoplanin in moderately and 
poorly differentiated squamous cell carcinoma signifies cytoskeletal 
modifications within the tumour nests thus explaining elevated 
cellular migration and possible role of podoplanin in squamous cell 
carcinoma. However, recent  investigations have revealed that  the 
invasion of SCC (squamous cell carcinomas) in the oral region does 
not solely depend on cellular dedifferentiation, rather on the 
attachment of specific tumour cells which express more podoplanin 
at the invasive site of the tumour 
(4 2 ,  7 3 )
.  Our finding demonstrated 
that  podoplanin expression may play a major role in the regulation 
of differentiation and progression of OSCC.  Furthermore, the 
expression analysis of podoplanin in the tissue samples could be 
useful to evaluate the tumour development in oral leukoplakia and 
act as a molecular biomarker for identification of advanced OSCC 
grades.   
 
 Podoplanin expression was evaluated as German 
Immunoreactive Scores (IRS) by multiplying quantity score and 
staining intensity scores (scores range from 0 to 15).  Score seven or 
above represent high podoplanin expression and a score below seven 
represents high podoplanin expression. In our study 35% of OSCC 
patients had shown low podoplanin expression and 65% of patients 
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had high podoplanin expression. In our study higher percentage of 
podoplanin expression was detected in females (66.7%) when 
compared to males,  however this difference was not statistically 
significant (P=0.122). Higher podoplanin expression was found in 
buccal mucosa (46.1%) as compared to alveolar mucosa (24.3%). 
Pearson's correlation of German Immunoreactive Score (signify low 
or high podoplanin expression) with gender and habit were not 
found to be statistically significant, which could have been due to 
small  sample size.   
 
 CLEC-2 (C-type lectin-like receptor-2) interacts with PLAG 
(platelet aggregation-stimulating domain) in the extrace llular region 
of podoplanin to induce inflammation and tumour progression, and 
this interaction can be obstructed by antibodies, including NZ -1, 
MS-1 and podoplanin antibodies (CasMabs). Antibodies can also 
target podoplanin in order to stop transformed ce ll growth and 
motility directly,  or can be incorporated into CAR -T cells.  Lectins 
represented by MASL can also target podoplanin to block the 
tumour progression and inflammation. Protein kinase A (PKA) and 
cyclin dependent kinase 5 (CDK5) can phosphorylate  serines on the 
intracellular tail to block cell  migration, probably by inhibiting 
interaction of ERM proteins that would otherwise lead to the 
activation of Rho GTPases and Rho -associated coiled-coil  kinase 
(ROCK). Podoplanin expression induces ROCK activ ity to promote 
squamous cell carcinoma survival and colony expansion 
(3 0 )
.   
 
 The most common oral  cancer sites were, floor of the mouth 
and the lips. Variations were seen in different countries such as in 
developed countries the tongue, while in Asian countries the buccal 
mucosa were the most common anatomical sites of OSCC. This 
differences can be explained with different etiological  factors. 
Generally,  in European countries alcohol and tobacco consumptions 
are the leading risk factors for oral cancer,  whereas in Asia betel  
quid chewing, tobacco chewing are major risk factors 
(9 1 )
.  The 
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development of oral  squamous cell carcinoma (OSCC) is a multi-
step process modulated by genetic, epigenetic and environmental  
factors.  In our study we found 75%, 70% and 65% of patients were 
tobacco and betel -quid chewers,  smokers,  and alcohol consumers 
respectively.  These self -destructive habits are very common in India 
and for these risk factors OSCC is one of the most widespread 
cancers in India and the major reason of death from cancer among 
males. We also found higher podoplanin expression in tobacco -betel  
quid chewers (56.7%), smokers (42.9%) and alcohol  consumers 
(53.9%) as compared to non-consumers. However, only alcohol 
consumption showed statistically significant correlation with higher 
podoplanin expressions (P=0.044). The higher incidence and 
prevalence rates of OSCC in India are due to various life style habits 
with  related risk factors like tobacco, betel quid chewing, smoking, 
and alcohol consumption, moreover, genetic factors and HPV 
infection also plays a crucial role in OSCC 
(1 ,  1 2 )
.  Our study also 
indicates the possible association between lifestyle habit related 
risk factors and higher podoplanin expression.  
 
 Previous studies have revealed that podoplanin expression 
was very low in normal oral epithelial  cells,  but higher in oral  
cancers 
(6 )
.  Podoplanin expression is expected to be much higher i n 
oral cancers than actually reported in different studies, because it is 
due to podoplanin expression is observed mostly in the invasive 
sites of oral cancers. Since more suspicious lesions of OSCC are 
mainly selected for biopsy, these results of podoplan in expression 
could be underestimated. Previous studies have also supported these 
underestimation of Podoplanin expression, as about 80% of oral 
leukoplakia cases expressing higher levels of podoplanin developed 
into oral cancer 
(3 5 )
.  Podoplanin expression is induced very early in 
the malignant transformation process, and therefore it may be used 
to detect premalignant lesions that  are bound to develop into oral  
cancer.  Pooled analysis of many retrospective studies have also 
demonstrated that over 46% of lesions with prominent podoplanin 
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expression advanced to OSCC. However, very less percentage of 
lesions without prominent podoplanin expression progressed to 
OSCC. These results indicate that podoplanin expression elevates 
the probabil ity of OSCC development 
(6 )
.  
 
 Furthermore, podoplanin expression was also found to be 
associated with OSCC mortali ty, as five year overall survival 
declines from 86 percent for oral  cancer patients with undetectable 
expression of podoplanin levels to 23 percent for oral  cancer cases 
with tumours exhibit ing higher levels of podoplanin expression 
(3 6 )
.  
These results indicated that  podoplanin expression promotes a 
threefold decrease in the five year survival for oral  cancer patients.  
However,  one of the studies demonstrated that  expression of 
podoplanin didn't  influence the five -year overall  survival or the 
five-year disease-free survival 
(3 9 )
.  Cirligeriu et  al .  (2014) revealed 
that  dual expression of podoplanin in tumour cells and lymphatics 
with specific patterns connected with histopathology and lymph 
node status in oral cancer,  exhibited the molecular basis for testing 
podoplanin as a potential  target  for anti D2-40 antibody based 
therapy 
(4 0 )
.
 
Prasad et al. stated that a high level of podoplanin 
expression was indicative of high incidence of lymph node 
metastasis and immature status in the d ifferentiation process of 
OSCC 
(4 1 )
.  Another previous analysis also described that  podoplanin 
could be uti lized as a biomarker for early oral carcinogenesis and 
for malignant transformation risk identification of pre -cancerous 
lesions and as a tumour development biomarker for advanced grades 
of OSCC 
(4 2 )
.   
 
 Podoplanin has appeared to be an obvious chemotherapeutic 
target for different cancers, hence, compounds that  target 
podoplanin are being used as anti -cancer reagents. Antibodies 
against podoplanin have been studied to be potential  anticancer 
agents. These experimental studies started with the NZ-1 
monoclonal antibody that targets the PLAG domains of human 
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podoplanin. At first ,  NZ-1 was used to hinder platelet  aggregation 
to glioma cells mediated by Podoplanin -CLEC2 interactions. A 
mouse-human chimeric antibody against human Podoplanin, 
chLpMab-7, was also experimented to block metastasis in a 
pulmonary xenograft mouse model. Other anti -podoplanin 
monoclonal antibodies such as murine and humanized MS -1 also 
obstructed podoplanin-CLEC2 interactions and could efficiently 
hinder lung tumour development by intravenous administration.  
 
 Genetically modified chimeric antigen receptor (CAR) -
transduced T-cells that  target podoplanin have also been tested to 
obstruct glioblastoma progression in mouse models.  The canc er 
specific monoclonal antibodies (CasMabs) are in use to counter 
cancer cells progression. It was also used to enhance chLpMab -23, 
which can obstruct  glioblastoma and OSCC development.  For 
instance, human OSCC cells that were subcutaneously administered 
into exposed mice, followed by 100 µg of i.p. administered 
ChLpMab-23, 6 times for above a 35 day period revealed a 3.5 -fold 
decrease in tumour weight than controls. This precursor of this 
CasMab antibody, LpMab-23, also displays minimum binding to 
nearby lymphatic endothelial cells  which express podoplanin.  These 
cancer-specific podoplanin antibodies cause minimum offsite 
targeting to offer a double-edged tool that can be used expression in 
normal tissues, and also as potential chemotherapeutic agents with 
reduced side effects. Podoplanin can also be targeted with other 
biological  chemicals, represented by Maackiaamurensis seed lectin 
(MASL). This compound is essentially an unintentional component 
of traditional medicines used to treat  cancers that have been  made 
from the Maackiaamurensis for decades.  The relationship between 
MASL and NZ-1 show that  both obstruct OSCC cell  migration and 
viability at similar concentrations.  This types of therapies could be 
valuable for oral cancer and precancerous lesions that  are intended 
to develop into OSCC 
(6 ,  3 2 )
.  
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CONCLUSION 
  
 Podoplanin is a transmembrane protein that is expressed 
mostly in lymphatic endothelium and in different normal t issues.  
The podoplanin expression was found higher in different squamous 
cell carcinoma (SCC) including oral  squamous  cell  carcinoma 
(OSCC). Therefore,  the expression of this Podoplanin in oral 
squamous cells would be helpful for diagnosis of early OSCC. Our 
present study evaluated the podoplanin expression of in OSCC and 
found that,  out of 20 OSCC cases 12 cases (60%) s howing 
podoplanin expression.  we observed grade -IV OSCC (poorly 
differentiated) exhibited significantly higher levels of podoplanin 
expression, as compared to moderately or well differentiated OSCC 
(P=0.004).  We also found higher podoplanin expression in tobacco-
betel quid chewers,  smokers and alcohol consumers as compared to 
non-consumers, which suggesting possible association between risk 
factors and podoplanin expression. Further investigations on the 
association between the podoplanin expression and ha bit-related 
factors in a larger sample size are needed.  
 
 Our study concludes that  the expression of podoplanin can be 
used as a biomarker for early detection of oral  squamous cell  
carcinoma (OSCC). Podoplanin  also helpful for risk assessment of 
premalignant oral lesions and as a molecular marker for advanced 
grades of OSCC. Further studies containing larger sample size are 
required to validate the clinical prospective of podoplanin as a 
molecular biomarker for  OSCC risk assessment.  Present study open 
up the new way to analyze the expression of podoplanin from OSCC 
biopsied t issues to evaluate the status of OSCC. In recent times,  
different anti -podoplanin based therapeutic agents, like CasMab 
anti-podoplanin, have been tested to improve the prognosis of 
cancer patients.  
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